In a new look at who sprays what and who gets sick, counties that use the most glyphosate, the active ingredient in Roundup, are reporting higher rates of late-stage non-Hodgkin lymphoma. The sharpest ...
The agency also granted traditional approval to later-line nivolumab indications for certain adults with the disease.
The FDA has approved the combination of nivolumab plus chemotherapy as first-line treatment for certain patients with stage III or IV classical Hodgkin lymphoma.The approval, for individuals aged 12 ...
The U.S. Food and Drug Administration on Friday approved Bristol Myers Squibb's combination treatment for adults and ...
CEO Richard Adcock used a presentation at the Citizens Life Sciences Conference to outline the company’s commercial progress ...
Executives from Caribou Biosciences (NASDAQ:CRBU) outlined upcoming clinical, regulatory, and financing milestones for its allogeneic cell therapy pipeline during a discussion at the Leerink Global ...
Methods developed and validated to establish the “World Bank of NK Cells” from healthy donors and cancer patientsSingle ...
BTK inhibitor monotherapy is foundational across several B-cell malignancies, with newer, more selective agents designed to preserve efficacy while improving tolerability relative to first-in-class ...
CD19 CAR-NK cell therapy with rituximab achieved durable complete responses in Waldenström Non-Hodgkin lymphoma, with up to 15 months of remission. The QUILT-106 study reported 100% disease control ...
Two patients with Waldenstrom’s NHL achieved complete remission with CAR NK cell therapy and rituximab, maintaining remission for 7 and 15 months without further treatment. The therapy is chemotherapy ...
Durable complete responses with CAR-NK + Rituximab in patients who failed current standards of care in Waldenstrom’s Non-Hodgkins lymphoma (NHL). Long-term evaluable patients demonstrate ongoing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results